Research programme: cancer therapeutics - Kainos Medicine

Drug Profile

Research programme: cancer therapeutics - Kainos Medicine

Alternative Names: Cytotoxic nucleic acid derivatives; KM101; KM301; KM601

Latest Information Update: 23 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Kainos Medicines
  • Developer Kainos Medicines; Undisclosed
  • Class Antineoplastics; Enzymes; Nucleosides; Nucleotides; Small molecules
  • Mechanism of Action Bromodomain and extraterminal domain protein inhibitors; DNA methylation inhibitors; EZH2 enzyme inhibitors; Nucleic acid modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Breast cancer; Haematological malignancies; Leukaemia; Myelodysplastic syndromes; Myeloid leukaemia; Non-Hodgkin's lymphoma; Solid tumours

Most Recent Events

  • 13 Apr 2018 Early research in Haematological malignancies in South Korea (PO) (Kainos Medicines pipeline, April 2018)
  • 13 Apr 2018 Early research in Solid tumours in South Korea (PO) (Kainos Medicines pipeline, April 2018)
  • 20 Oct 2015 Early research in Breast cancer in South Korea (Parenteral) (Kainos Medicines pipeline, October 2015)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top